Distribution of apomorphine enantiomers in plasma, brain tissue and striatal extracellular fluid

European Journal of Pharmacology

Volumn 329, Issue 1, 1997, Pages 9-15

  Sam, Exaud ^a   Sarre, Sophie ^b   Michotte, Yvette ^b   Verbeke, Norbert ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

Author keywords

Active; Apomorphine; Biodistribution; Enantiomer; Stereoselective; Uptake

Indexed keywords

APOMORPHINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BEHAVIOR; BLOOD BRAIN BARRIER; BRAIN; BRAIN CORTEX; BRAIN REGION; CEREBELLUM; CONTROLLED STUDY; CORPUS STRIATUM; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG DISTRIBUTION; ENANTIOMER; EXTRACELLULAR FLUID; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; MICRODIALYSIS; NONHUMAN; PRIORITY JOURNAL; RAT; STEADY STATE; STEREOSPECIFICITY; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0031577184     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(97)10082-6     Document Type: Article

References (19)

1. Biachi G., Landi M. Determination of apomorphine in rat plasma and brain by high-performance chromatography with electrochemical detection. J. Chromatogr. 338:1985;230-235.
2. Butterworth R.F., Poignant J., Barbeau A. Apomorphine and piribedil in rats: biochemical and pharmacological studies. Adv. Neurol. 9:1975;307-326.
3. Colpaert F.C., Van Bever W., Leysen J. Apomorphine: chemistry, pharmacology biochemistry. Int. Rev. Neurobiol. 19:1976;225-269.
4. Dannielle L., Mary L.W., Jacob I.S. Apomorphine for motor fluctuations and freezing in Parkinson's disease. Ann. Pharmacother. 29:1995;282-288.
5. D'Costa D.F., Abbott R.J., Pye I.F., Milac P.A. The apomorphine test in parkinsonian syndromes. J. Neurol. Neurosurg. Psychiatry. 54:1991;870-872.
6. Gasser T., Schwarz J., Arnold G., Trenkwalder C., Oertel W.H. Apomorphine test for dopaminergic responsiveness in patients with previously untreated Parkinson's disease. Arch. Neurol. 49:1992;1131-1134.
7. Goetz, C.G., Diederich, N.J., 1992. Dopaminergic agonists in the treatment of Parkinson's disease. In: Cedarbaum, J.M., Gancher, S.T. (Eds.), Parkinson's disease. W.B. Saunders, Philadelphia, PA, pp. 527-540.
8. Goldstein M., Freedman I., Backstrom T. The inhibition of catecholamine biosynthesis by apomorphine. J. Pharm. Pharmacol. 22:1970;715-717.
9. Hofstee D.J., Neef C., Van Laar T., Jansen E.N. Pharmacokinetics of apomorphine in Parkinson's disease: plasma and cerebrospinal fluid levels in relation to motor responses. Clin. Neuropharmacol. 17:1994;45-52.
10. Hughes A.J., Lees A.J., Stern G.M. Apomorphine test to predict dopaminergic responsiveness in parkinsonian syndromes. Lancet. 336:1990;32-35.
11. Kebabian J.W. A sensitive enzymatic radioisotopic assay for apomorphine. J. Neurochem. 30:1978;1143-1148.
12. Melzacka M., Wiszniowska G., Vetulani J. The distribution of apomorphine in rat brain: possible behavioural correlates. Pol. J. Pharmacol. Pharm. 30:1978;335-345.
13. Przedborski S., Levivier M., Raftopoulos C., Naini A.B., Hildebrand J. Peripheral and central pharmacokinetics of apomorphine and its effect on dopamine metabolism in humans. Mov. Disord. 10:1995;28-36.
14. Sam E., Verbeke N. Free radical scavenging properties of apomorphine enantiomers and dopamine: possible implication in their mechanism of action in parkinsonism. J. Neural. Transm. (P-D Sect.). 10:1995;115-127.
15. Sam E., Augustijns P., Verbeke N. Stability of apomorphine in plasma and its determination by high-performance liquid chromatography with electrochemical detection. J. Chromatogr. B. 658:1994;311-317.
16. Seeman P., Van Tol H.H.M. Dopamine D-4 receptors bind inactive (+) aporphines suggesting neuroleptic role. Sulpride not stereoselective. Eur. J. Pharmacol. 233:1993;173-174.
17. Smith R.V., Velagapudi R.B., McLean A.M., Wilcox R.E. Interaction of apomorphine with serum and tissue proteins. J. Med. Chem. 28:1985;613-620.
18. Van Tol H.H.M., Bunzow J.R., Guan H.C., Sunahara R.K., Seeman P., Niznik H.B., Civelli O. Cloning of the gene for a human dopamine D-4 receptor with high affinity for the antipsychotic clozapine. Nature. 350:1991;310.
19. Westerink B.H., Horn A.S. Do neuroleptics prevent the penetration of dopamine agonists into the brain? Eur. J. Pharmacol. 58:1979;39-48.